৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬



Quantity:
Products
Payment
Delivery
Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is appropriate.
Pharmacology
Linagliptin: DPP-4 inhibitor. Prevents degradation of incretin hormones (GLP-1, GIP), increasing insulin secretion from pancreatic β-cells in a glucose-dependent manner and reducing glucagon secretion from α-cells.
Metformin Hydrochloride: Biguanide antihyperglycemic. Lowers basal and postprandial plasma glucose by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity.
Dosage & Administration
Immediate-release tablets:
Max dose: Linagliptin 2.5 mg + Metformin 1000 mg twice daily with meals.
Starting dose:
If not on Metformin: Linagliptin 2.5 mg + Metformin 500 mg twice daily.
If already on Metformin: Linagliptin 2.5 mg + current Metformin dose twice daily.
If already on both: Switch to combination with same doses.
Extended-release tablets:
Max dose: Linagliptin 5 mg + Metformin 2000 mg once daily with meal.
Starting dose:
If not on Metformin: Linagliptin 5 mg + Metformin 1000 mg once daily.
If already on Metformin: Linagliptin 5 mg + similar Metformin dose once daily.
If already on immediate-release: Switch to extended-release with equivalent total daily dose.
Interactions
Cationic drugs (e.g., cimetidine, digoxin, morphine): May compete with Metformin for renal tubular secretion → monitor closely.
Carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide): May increase risk of metabolic acidosis.
P-gp/CYP3A4 inducers (e.g., rifampin): Reduce Linagliptin exposure → alternative therapy recommended.
Drugs affecting glycemic control (e.g., corticosteroids, diuretics, estrogens, thyroid products): May cause hyperglycemia → monitor closely.
Contraindications
Renal impairment (risk of Metformin accumulation and lactic acidosis).
Acute or chronic metabolic acidosis (including diabetic ketoacidosis).
Hypersensitivity to Linagliptin or Metformin.
Side Effects
Common: Nasopharyngitis, diarrhea.
Hypoglycemia more frequent when combined with sulfonylureas.
Pregnancy & Lactation
No adequate studies; use only if clearly needed.
Caution advised during lactation.
Precautions & Warnings
Lactic acidosis: Discontinue Metformin immediately if suspected.
Pancreatitis: Reported post-marketing; discontinue if suspected.
Temporarily stop before radiologic studies with contrast or major surgery.
Metformin may lower Vitamin B12 levels → monitor hematologic parameters annually.
Alcohol increases risk of lactic acidosis.
Patients should carry medical identification for diabetes emergencies.





$4f
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Lijenta MX 2.5/1000 mg Tablet is to be taken with food.
Lijenta MX 2.5/1000 mg Tablet is a combination of two antidiabetic medicines: Metformin and Linagliptin. Metformin is an antidiabetic medication (biguanide). It works by lowering the glucose production in the liver, delaying glucose absorption from the intestines and increasing the body's sensitivity to insulin. Linagliptin is a DPP-4 inhibitor which works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces both fasting and postmeal sugar levels. Together, they provide better control of blood sugar.
If you miss a dose of Lijenta MX 2.5/1000 mg Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.





